What is Aetion?
Aetion operates at the intersection of healthcare and technology, specializing in the delivery of real-world evidence (RWE) to life sciences companies. The Aetion Evidence Platform is central to its operations, leveraging advanced analytics to process vast amounts of real-world data. This enables the generation of scientifically rigorous insights into treatment efficacy, economic impact, and patient outcomes. With a foundation built on decades of expertise in epidemiology and health outcomes research, Aetion empowers critical decision-making across the healthcare spectrum, from treatment development and commercialization strategies to payment innovation.
How much funding has Aetion raised?
Aetion has raised a total of $203.2M across 3 funding rounds:
Series A
$11.2M
Series B
$82M
Series C
$110M
Series A (2017): $11.2M with participation from Flare Capital Partners and Lakestar
Series B (2020): $82M led by EDBI, Flare Capital Partners, Oxeon, JJDC, Lakestar, Greenspring Associates, and Amgen Business Development
Series C (2021): $110M supported by New Enterprise Associates, Flare Capital Partners, B Capital Group, Foresite Capital, and Warburg Pincus
Key Investors in Aetion
Flare Capital Partners
Flare Capital Partners is a leading investor focused on healthcare technology, collaborating with entrepreneurs to enhance healthcare outcomes and reduce costs. The firm supports a diverse portfolio of companies addressing critical challenges within the healthcare industry.
Lakestar
Lakestar is a venture capital firm dedicated to partnering with visionary tech entrepreneurs to fund innovative ideas and companies that shape modern life, with a focus on sectors such as Deep Tech, Healthcare, and Fintech.
New Enterprise Associates
New Enterprise Associates (NEA) is a venture capital firm focused on helping entrepreneurs build businesses, with a history of investing in transformative companies across various sectors.
What's next for Aetion?
With substantial backing and a robust platform, Aetion is well-positioned for accelerated expansion and innovation. The company's focus on generating high-quality real-world evidence is increasingly vital as the healthcare industry navigates complex challenges related to value-based care, drug development, and market access. Future strategic initiatives are likely to involve further enhancement of its analytical capabilities, expansion into new therapeutic areas, and forging deeper partnerships with life sciences organizations and payers. Continued investment will fuel Aetion's ability to shape healthcare's future by providing the data-driven clarity needed for informed decision-making.
See full Aetion company page
